Medicenna Therapeutics (TSE:MDNA) Hits New 1-Year Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) reached a new 52-week low during trading on Thursday . The company traded as low as C$0.34 and last traded at C$0.35, with a volume of 54128 shares trading hands. The stock had previously closed at C$0.35.

Medicenna Therapeutics Stock Performance

The company has a market cap of C$32.30 million, a price-to-earnings ratio of -1.59 and a beta of 2.96. The firm has a 50 day moving average price of C$0.40 and a two-hundred day moving average price of C$0.63. The company has a quick ratio of 4.65, a current ratio of 1.52 and a debt-to-equity ratio of 4.79.

Medicenna Therapeutics (TSE:MDNA) last announced its earnings results on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. As a group, equities analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.